– USA, WA – Trupanion, Inc. (NYSE: TRUP) announced its Board of Directors has appointed Robin Ferracone to the Board as a member of its Compensation Committee. Murray Low, Chairman of the Board, stated, “Robin is a recognized world leader on corporate compensation, and we look forward to her expertise and contribution to the Board.”
Trupanion CEO, Darryl Rawlings commented, “I am very excited about Robin joining our Board, bringing her strategic compensation expertise and enthusiasm for pets to the group.”
Robin Ferracone brings a wealth of knowledge and expertise to Trupanion as the CEO of Farient Advisors, a performance advisory and strategic compensation firm. Previously she was at Marsh & McLennan Companies, Inc.; a global professional services firm in the areas of risk, strategy and human capital. At Marsh McLennan, she was President of the Global Human Capital Business, domiciled in 40 offices around the world, including Latin America, Brazil, Europe, India and China.
Regarding the new appointment, Ferracone stated “The mission to help companion cats and dogs gain access to the best medical care, its strong growth prospects, and its highly capable management team are what first attracted me to the company. However, as I’ve gotten to know Trupanion better, I also have been struck by how the employees have internalized the company’s values and created a powerful corporate culture that make Trupanion an exceptional place to work.”
A Harvard Business School graduate, Ferracone was named to the prestigious 2014 NACD Directorship 100, her fourth time receiving this award, making her one of the most influential people in corporate governance and in the boardroom. As the author of the book “Fair Pay, Fair Play: Aligning Executive Performance and Pay,” she is highly regarded for her expertise in performance measurement and linking executive compensation with corporate strategy. She is also an experienced director having served on a number of boards, including her current appointments on the board of two Oaktree Capital mutual funds and Duke University, where she earned her BA in Economics and Management Science, and her prior appointment on the board of PayScale, Inc. (a private equity backed cloud-based compensation data and software company). She also served as a non-Executive Chairman of A Breed Apart Veterinary Centers, which was sold to VCA Inc.
“I’m very excited about joining Trupanion’s board of directors as the company begins its next chapter as a public company,” said Ferracone whose appointment to Trupanion’s Board will be effective December 31, 2014.”
About Trupanion
Founded in 2000, Trupanion is an industry-leading, direct-to-consumer, monthly subscription business that provides medical plans for cats and dogs in the United States, Canada and Puerto Rico through its affiliated entities. With 207,843 total enrolled pets (as of 9/30/2014), Trupanion’s mission is to help the pets we all love receive the best veterinary care. The Trupanion pet medical insurance plan is a simple, fair and comprehensive policy that pays 90% of the covered veterinary costs for pet’s illness and injury claims. Trupanion’s shares are traded on the New York Stock Exchange under the ticker symbol TRUP.
Founded in 2000, Trupanion is an industry-leading, direct-to-consumer, monthly subscription business that provides medical plans for cats and dogs in the United States, Canada and Puerto Rico through its affiliated entities. With 207,843 total enrolled pets (as of 9/30/2014), Trupanion’s mission is to help the pets we all love receive the best veterinary care. The Trupanion pet medical insurance plan is a simple, fair and comprehensive policy that pays 90% of the covered veterinary costs for pet’s illness and injury claims. Trupanion’s shares are traded on the New York Stock Exchange under the ticker symbol TRUP.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
